Literature DB >> 27077907

Association of BIM Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma.

Shang-Gin Wu1, Yi-Nan Liu2, Chong-Jen Yu2, Pan-Chyr Yang2, Jin-Yuan Shih3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27077907     DOI： 10.1001/jamaoncol.2016.0016

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  12 in total

Review 1.  Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.

Authors:  Kenichi Suda; Paul A Bunn; Christopher J Rivard; Tetsuya Mitsudomi; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-09-15       Impact factor: 15.609

Review 2.  Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors.

Authors:  Shi-Yong Sun
Journal:  Front Med       Date:  2022-09-24       Impact factor: 9.927

3.  Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.

Authors:  Shouheng Lin; Guohua Huang; Lin Cheng; Zhen Li; Yiren Xiao; Qiuhua Deng; Yuchuan Jiang; Baiheng Li; Simiao Lin; Suna Wang; Qiting Wu; Huihui Yao; Su Cao; Yang Li; Pentao Liu; Wei Wei; Duanqing Pei; Yao Yao; Zhesheng Wen; Xuchao Zhang; Yilong Wu; Zhenfeng Zhang; Shuzhong Cui; Xiaofang Sun; Xueming Qian; Peng Li
Journal:  MAbs       Date:  2018-10-02       Impact factor: 5.857

4.  Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.

Authors:  Jinjing Xia; Hao Bai; Bo Yan; Rong Li; Minhua Shao; Liwen Xiong; Baohui Han
Journal:  Oncotarget       Date:  2017-07-20

Review 5.  [Effect and Significance of BIM on Non-small Cell Lung Cancer].

Authors:  Jingfang Wang; Tao Xin
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-11-20

6.  BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer: An updated meta-analysis.

Authors:  Wenxia Su; Xiaoyun Zhang; Xin Cai; Meiyu Peng; Fengbin Wang; Yuliang Wang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

7.  The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer.

Authors:  Yen-Ting Lin; Yi-Nan Liu; Jin-Yuan Shih
Journal:  Front Oncol       Date:  2019-09-23       Impact factor: 6.244

Review 8.  Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review.

Authors:  Yijia Guo; Jun Song; Yanru Wang; Letian Huang; Li Sun; Jianzhu Zhao; Shuling Zhang; Wei Jing; Jietao Ma; Chengbo Han
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

9.  Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors.

Authors:  Nancy K Gillis; Daniel M Rotroff; Tania E Mesa; Jiqiang Yao; Zhihua Chen; Michael A Carulli; Sean J Yoder; Christine M Walko; Jamie K Teer; Howard L McLeod
Journal:  Oncotarget       Date:  2017-12-04

10.  Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients.

Authors:  Xingya Ruan; Yonghua Sun; Wei Wang; Jianwei Ye; Daoyun Zhang; Ziying Gong; Mingxia Yang
Journal:  Oncol Lett       Date:  2020-03-05       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.